Healio

FDA approves expanded indication of Uzedy for bipolar I disorder

This is a developing news story. Please check back soon for updates. The FDA approved extended-release Uzedy for the ...

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to ...
Medscape

Second-generation Antipsychotics: Not All Equal

SCOTTSDALE, Arizona ― Second-generation antipsychotics (SGAs) differ with regard to efficacy and side effect profiles for the treatment of first-episode psychosis, according to the results of a new ...
Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...